Amniox Medical, Inc, a TissueTech, Inc, company (Miami, FL), announced that a phase 2 pilot trial demonstrated successful outcomes for the treatment of complex diabetic foot ulcers (DFUs) with a newer cryopreserved human umbilical cord product. The product, TTAX01, is an investigational biologic form of the company’s proprietary NEOX CORD 1K, a cryopreserved umbilical cord proven to promote healing in complex wounds. In the study published online in Wound Repair and Regeneration, TTAX01 demonstrated confirmed closure in 16 of 32 wounds by the end of the 16-week study period with a median 1 product application. In addition, in cases with biopsy-confirmed osteomyelitis, confirmed closure occurred in 10 (50%) wounds.
Visit www.amnioxmedical.com for more information.